SEAMAN, JONATHAN,MANIKWAR, PRAKASH,LOBO, BRIAN,HAMMOND, SCOTT A.,OBERST, MICHAEL,MAZOR, YARIV,POLLIZZI, KRISTEN,CARLESSO, GIANLUCA,SCHOFIELD, DARREN,DRABIC, STACEY,DOBSON, CLAIRE LOUISE,MORROW, MICHEL
申请号：
ARP170101161
公开号：
AR108377A1
申请日:
2017.05.04
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
Claim 1: a Protein, characterized in that it comprises a First binding domain (BD1) that binds to a First Epitope,A Second binding domain (BD2) which binds to an epitope and a Second FC region comprising the CH2 and CH3 Domains； where the FC region comprising a BD2 in a Loop exposed to Solvent in the dOMINIO CH2, CH3 domain or at the interface of the CH2 and CH3 Domains； and where the Protein is for the Union to each Bivalent between the first and second epitopes.Claim: a 38 biespec u00edfica Binding Protein that binds to pd-1 and ctla-4,First characterized in that it comprises a Peptide comprising the amino acid sequence of the SEQ ID no. 5 and a Second Peptide comprising the amino acid sequence of the SEQ ID no. 6.Claim 49: an Antibody or an Antigen binding Fragment of the same, which binds to tim3, characterized in that it comprises a heavy chain that includes CDR1,CDR2 and CDr3 and a light chain comprising CDR1, CDR2, CDR1 and CDr3, where the heavy chain comprises SEQ ID no. 79, CDR2 of the heavy chain comprises SEQ ID no. 80The heavy chain CDr3 comprises SEQ ID no. 81 of the CDR1 and light chain comprising SEQ ID no. 82, CDR2 of light chain comprising SEQ ID no. 83The CDr3 of the light chain comprising SEQ ID no. 84.Claim 56: a method of treatment or prevention of cancer in a subject.Wherein Said method comprises Administering the Protein or the Antibody of any of claims 1 - 51 to the subject.Reivindicación 1: Una proteína, caracterizada porque comprende un primer dominio de unión (BD1) que se une a un primer epitope, un segundo dominio de unión (BD2) que se une a un segundo epitope y una región Fc que comprende los dominios CH2 y CH3； en donde la región Fc comprende un BD2 en un bucle expuesto al solvente en el dominio CH2, el dominio CH3 o en la interfase de los dominios CH2 y CH3； y en donde la proteína es bivalente para la unión a cada uno entre el primer y el segundo epitopes. Reivindicación 38: Una proteína de unión biespecífica que se une a PD-1 y CTLA-4
